ESAI.Y logo

Eisai OTCPK:ESAI.Y Stock Report

Last Price

US$6.89

Market Cap

US$7.8b

7D

-1.4%

1Y

-43.9%

Updated

23 Dec, 2024

Data

Company Financials +

ESAI.Y Stock Overview

Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. More details

ESAI.Y fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance1/6
Financial Health4/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

Eisai Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eisai
Historical stock prices
Current Share PriceJP¥6.89
52 Week HighJP¥13.15
52 Week LowJP¥6.79
Beta-0.14
1 Month Change-8.26%
3 Month Change-29.26%
1 Year Change-43.94%
3 Year Changen/a
5 Year Changen/a
Change since IPO-55.61%

Recent News & Updates

Recent updates

Shareholder Returns

ESAI.YUS PharmaceuticalsUS Market
7D-1.4%-0.3%-2.7%
1Y-43.9%7.9%23.4%

Return vs Industry: ESAI.Y underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: ESAI.Y underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is ESAI.Y's price volatile compared to industry and market?
ESAI.Y volatility
ESAI.Y Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ESAI.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ESAI.Y's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
194111,067Haruo Naitowww.eisai.co.jp

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.

Eisai Co., Ltd. Fundamentals Summary

How do Eisai's earnings and revenue compare to its market cap?
ESAI.Y fundamental statistics
Market capUS$7.78b
Earnings (TTM)US$262.02m
Revenue (TTM)US$4.82b

29.7x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ESAI.Y income statement (TTM)
RevenueJP¥753.22b
Cost of RevenueJP¥157.26b
Gross ProfitJP¥595.97b
Other ExpensesJP¥555.00b
EarningsJP¥40.97b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 07, 2025

Earnings per share (EPS)145.34
Gross Margin79.12%
Net Profit Margin5.44%
Debt/Equity Ratio21.7%

How did ESAI.Y perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

112%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eisai Co., Ltd. is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research